Business Context and Reporting Period
This Form 8-K reports the consummation of the Initial Public Offering (IPO) by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc., as indicated in the metadata request) on February 23, 2022. The filing covers events occurring between February 17, 2022, and February 23, 2022. The Company is a Cayman Islands exempted company and an emerging growth company.
Key Financial Metrics
- IPO Gross Proceeds: $287,500,000 from the sale of 28,750,000 Units at $10.00 per Unit (including full exercise of the over-allotment option).
- Private Placement Proceeds: $14,645,000 from the sale of 9,763,333 Private Warrants to the Sponsor at $1.50 per warrant.
- Total Funds in Trust: $294,687,500 deposited into a U.S.-based trust account.
- Warrant Exercise Price: $11.50 per share for public and private warrants.
- Debt and Liquidity: The filing does not provide specific debt figures or operating cash flow data, as the Company is a special purpose acquisition company (SPAC) in its pre-business combination phase.
Material Changes
This filing represents the Company's transition from a private entity to a publicly traded company on The Nasdaq Stock Market LLC. Key changes include:
- Issuance of 28,750,000 Units (Class A ordinary shares and redeemable warrants).
- Completion of the private sale of warrants to the Sponsor.
- Forfeiture of up to 937,500 Founder Shares was avoided due to the full exercise of the underwriters' over-allotment option.
Outlook, Risks, and Contingencies
Trust Account Restrictions: Funds in the trust account ($294,687,500) are generally not accessible until the completion of an initial business combination, shareholder redemption, or dissolution. Interest earned may be used to pay taxes or up to $100,000 for dissolution expenses.
Combination Period: The Company must complete an initial business combination within 15 months of the IPO closing or during an Extension Period as defined in the Registration Statement. Failure to do so may result in the redemption of all public shares.
Risks: The filing notes standard SPAC risks, including the potential inability to complete a business combination within the specified timeframe and the dilution effects of warrants and founder shares.
Investor Verification Checklist
- Verify the exact terms of the "Extension Period" referenced in the Registration Statement to understand the full timeline for a business combination.
- Confirm the specific underwriting discounts and offering expenses deducted from the gross proceeds to determine net cash available outside the trust.
- Review the Amended and Restated Memorandum and Articles of Association (Exhibit 3.1) for details on redemption rights and voting thresholds.
- Check the status of the 7,187,500 Founder Shares held by the Sponsor and their voting rights relative to public shares.